Creapharm Parenterals Overview
- Year Founded
-
1998

- Status
-
Acquired/Merged
- Employees
-
16

- Latest Deal Type
-
M&A
- Financing Rounds
-
1
Creapharm Parenterals General Information
Description
Manufacturer of pharmaceuticals and clinical supplies. The company primarily focuses on formulation, aseptic filling, and lyophilization of APIs, cytotoxics and other high potency drugs, as well as biologics.
Contact Information
Corporate Office
- 10 Rue des Boules
- 63200 Riom
- France
Corporate Office
- 10 Rue des Boules
- 63200 Riom
- France
Creapharm Parenterals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Creapharm Parenterals Signals
Creapharm Parenterals Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Creapharm Parenterals FAQs
-
When was Creapharm Parenterals founded?
Creapharm Parenterals was founded in 1998.
-
Where is Creapharm Parenterals headquartered?
Creapharm Parenterals is headquartered in Riom, France.
-
What is the size of Creapharm Parenterals?
Creapharm Parenterals has 16 total employees.
-
What industry is Creapharm Parenterals in?
Creapharm Parenterals’s primary industry is Biotechnology.
-
Is Creapharm Parenterals a private or public company?
Creapharm Parenterals is a Private company.
-
What is Creapharm Parenterals’s current revenue?
The current revenue for Creapharm Parenterals is
. -
Who are Creapharm Parenterals’s investors?
Créapharm Group has invested in Creapharm Parenterals.
-
When was Creapharm Parenterals acquired?
Creapharm Parenterals was acquired on 16-Jan-2012.
-
Who acquired Creapharm Parenterals?
Creapharm Parenterals was acquired by Carbogen Amcis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »